HROWHarrow, Inc.
Is the price fair?
Priced for +44% a year vs +39% a year delivered. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~44% a year FCF growth. The price demands more than its three-year revenue growth of 39% a year, priced for acceleration.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What HROW's price assumes
Harrow, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 5.61× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.32%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +44%
Growth the price implies · The price pays for +44% free cash flow growth a year for a decade; revenue has grown +39% a year over the last three.
- Price / book
- 102
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 102
- EV / EBIToperating margin −1.0%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 6.40
- Free cash flow, trailing twelve months
- $5.0M
- Market capitalisation
- $1.55B
- 3-year revenue growth
- +39%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #22 of 41 by RyuScore